Dataset Information

Identification and partial characterization of a novel membrane glycoprotein induced by amino acid deprivation in renal epithelial cells.

ABSTRACT: We have identified a protein of 110 kDa in the renal epithelial cell line NBL-1. which is induced on incubation of the cells in an amino-acid-free medium. The protein was purified on conA-Sepharose and subjected to N-terminal sequencing. The sequence obtained. VDRINFKT, does not correspond to any protein in the databases. Antipeptide antibodies made to this sequence recognised a single protein of 110 kDa in whole cell membranes and in a conconavalin A protein extract. Using the antibody on Western blots, the protein was induced 2.5-3 fold in 10-15 h and the induction was inhibited by cycloheximide and tunicamycin. The protein was found also in rat liver plasma membranes. A procedure for the partial purification of this protein from rat liver is described, and some internal sequence is reported. The possible relationship of the induction of this novel protein to the induction of amino acid transport in these cells by amino acid deprivation is discussed.

SUBMITTER: Burston J

PROVIDER: S-EPMC1218225 | biostudies-other | 1997 Mar

REPOSITORIES: biostudies-other

ACCESS DATA

Similar Datasets

Project description:Cancer is caused by uncontrollable growth of neoplastic cells, leading to invasion of adjacent and distant tissues resulting in death. Cancer cells have specific nutrient(s) auxotrophy and have a much higher nutrient demand compared to normal tissues. Therefore, different metabolic inhibitors or nutrient-depleting enzymes have been tested for their anti-cancer activities. We review recent available laboratory and clinical data on using various specific amino acid metabolic pathways inhibitors in treating cancers. Our focus is on glutamine, asparagine, and arginine starvation. These three amino acids are chosen due to their better scientific evidence compared to other related approaches in cancer treatment. Amino acid-specific depleting enzymes have been adopted in different standard chemotherapy protocols. Glutamine starvation by glutaminase inhibitior, transporter inhibitor, or glutamine depletion has shown to have significant anti-cancer effect in pre-clinical studies. Currently, glutaminase inhibitor is under clinical trial for testing anti-cancer efficacy. Clinical data suggests that asparagine depletion is effective in treating hematologic malignancies even as a single agent. On the other hand, arginine depletion has lower toxicity profile and can effectively reduce the level of pro-cancer biochemicals in patients as shown by ours and others' data. This supports the clinical use of arginine depletion as anti-cancer therapy but its exact efficacy in various cancers requires further investigation. However, clinical application of these enzymes is usually hindered by common problems including allergy to these foreign proteins, off-target cytotoxicity, short half-life and rapidly emerging chemoresistance. There have been efforts to overcome these problems by modifying the drugs in different ways to circumvent these hindrance such as (1) isolate human native enzymes to reduce allergy, (2) isolate enzyme isoforms with higher specificities and efficiencies, (3) pegylate the enzymes to reduce allergy and prolong the half-lives, and (4) design drug combinations protocols to enhance the efficacy of chemotherapy by drug synergy and minimizing resistance. These improvements can potentially lead to the development of more effective anti-cancer treatment with less adverse effects and higher therapeutic efficacy.

Dataset Information

Identification and partial characterization of a novel membrane glycoprotein induced by amino acid deprivation in renal epithelial cells.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets